Metraipolis › archive › dc_64f80225532c

Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group — Europe PMC PMID:42452684

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42452684
DOI
10.3390/jcm15135224
License (as archived)
solo-consultazione
Archived
2026-10-18T11:27:40.771Z
SHA-256 of the archived text
b94da71f60987b56b68f264715d79c0dc76cb348c5a401bebe31ff22a5be6da0
Stable URL of this page
https://metraipolis.com/documento/dc_64f80225532c

How to cite

Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group — Europe PMC PMID:42452684 — Europe PMC (en), https://europepmc.org/article/MED/42452684 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_64f80225532c (Metraipolis archive dc_64f80225532c, sha256 b94da71f60987b56b68f264715d79c0dc76cb348c5a401bebe31ff22a5be6da0)
BibTeX
@misc{dc64f80225532c,
  title = {Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group — Europe PMC PMID:42452684},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42452684},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_64f80225532c; sha256 b94da71f60987b56b68f264715d79c0dc76cb348c5a401bebe31ff22a5be6da0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452684. Agents can read the archived copy with the MCP tool read_document.